A prospective single-blind comparative study on the efficacy and safety of ilaprazole 10 mg versus omeprazole 20 mg in patients with gastroesophageal reflux disease and erosive gastritis
Review of Clinical Pharmacology and Pharmacokinetics · 06.08.2026 · 40 · 31-48
DOI: 10.61873/rcpp.40.e196749 ↗Kurz gefasst
Fachartikel in der Zeitschrift Review of Clinical Pharmacology and Pharmacokinetics, online erschienen am 06.08.2026. Verfasst von Arbind Kumar Choudhary.
Abstract (Originalsprache)
Background
Gastroesophageal reflux disease (GERD) is a prevalent chronic acid-related disorder that substantially impairs patient quality of life. Proton pump inhibitors (PPIs) are established therapy; however, first-generation agents such as omeprazole show clinically relevant inter-individual variability related in part to cytochrome P450 2C19 (CYP2C19) metabolism. Ilaprazole, a newer PPI with predominant cytochrome P450 3A4 (CYP3A4) metabolism and a longer elimination half-life, may provide more consistent acid suppression, but direct comparative data in Indian patients with GERD and erosive gastritis using validated quality-of-life tools remain limited.
Aim
To compare the clinical efficacy, health-related quality-of-life outcomes, and safety of ilaprazole 10 mg once daily versus omeprazole 20 mg once daily over eight weeks in patients with symptomatic GERD and endoscopically confirmed erosive gastritis. Erosive esophagitis was not required for inclusion and was not the primary condition studied. Methodology: A prospective, single-center, single-blind, comparative clinical study was conducted at VMKVMC&H, Salem, Tamil Nadu. Sixty patients fulfilling the inclusion criteria were randomly assigned in a 1:1 ratio to either ilaprazole 10 mg (n=30) or omeprazole 20 mg (n=30) once daily before breakfast for eight weeks. Participants were blinded to treatment allocation, while treating investigators were aware of allocation for dispensing and safety monitoring. Primary outcomes were change in GERD symptom count and health-related quality of life assessed using the 25-item QOLRAD questionnaire across five domains: Emotional distress, sleep disturbance, food/drink problems, physical/social functioning, and vitality. The theoretical QOLRAD total score range is 25-175, with higher scores indicating better quality of life. Adverse drug reactions, adherence, and concomitant/rescue medication use were assessed at follow-up visits. Baseline imbalances in symptom count and choking sensation were taken into account when analysing efficacy outcomes.
Results
The groups were comparable in age (35.8±6.3 vs 37.2±4.8 years; p =0.352), and sex distribution was similar but not identical (male 53.3% vs 50.0%; p =1.000). Baseline QOLRAD total scores were comparable (34.07±9.10 vs 33.13±7.73; p =0.965). Baseline symptom count was higher in the omeprazole group (7.90±0.61 vs 7.10±0.96; p
Zitieren
APA
Choudhary, A. K. (2026). A prospective single-blind comparative study on the efficacy and safety of ilaprazole 10 mg versus omeprazole 20 mg in patients with gastroesophageal reflux disease and erosive gastritis. Review of Clinical Pharmacology and Pharmacokinetics, 40, 31-48. https://doi.org/10.61873/rcpp.40.e196749
Vancouver
Choudhary AK. A prospective single-blind comparative study on the efficacy and safety of ilaprazole 10 mg versus omeprazole 20 mg in patients with gastroesophageal reflux disease and erosive gastritis. Review of Clinical Pharmacology and Pharmacokinetics. 2026;40:31-48. doi:10.61873/rcpp.40.e196749
BibTeX
@article{Choudhary2026,
author = {Choudhary, Arbind Kumar},
title = {A prospective single-blind comparative study on the efficacy and safety of ilaprazole 10 mg versus omeprazole 20 mg in patients with gastroesophageal reflux disease and erosive gastritis},
journal = {Review of Clinical Pharmacology and Pharmacokinetics},
year = {2026},
volume = {40},
pages = {31--48},
doi = {10.61873/rcpp.40.e196749}
}
EUVIMED